Inherited thrombophilias in pregnant patients

Prenatal and Neonatal Medicine

Volumn 6, Issue 1, 2001, Pages 3-14

  Lockwood, C J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fetal sequelae; Inherited coagulopathies; Maternal sequelae; Pregnancy; Thromboembolic disease

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 5 DEFICIENCY; DEEP VEIN THROMBOSIS; FEMALE; HIGH RISK PREGNANCY; HOMOZYGOSITY; HUMAN; LUNG EMBOLISM; MATERNAL MORBIDITY; PERINATAL MORBIDITY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PUERPERIUM; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0035035758     PISSN: 13598635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Inherited thrombophilia and pregnancy
2. Prothrombin and Factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
3. Increased fetal loss in women with heritable thrombophilia
4. Underlying disorders associated with severe early onset preeclampsia
5. Preeclampsia is associated with a reduced response to activated protein C
6. Increased frequency of genetic thrombophilia in women with complications of pregnancy
7. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications
8. Severe preeclampsia and high frequency of genetic thrombophilic mutations
9. Thrombophilia-associated pregnancy wastage
10. Tissue factor and hemostasis
11. Regulation of the tissue factor pathway
12. Amniotic fluid contains tissue factor, a potent initiator of coagulation
13. Progestational regulation of human endometrial stromal cell factor expression during decidualization
14. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception
15. Heritable coagulopathies in pregnancy
16. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
17. Anticoagulant properties of the vascular endothelium
18. Human plasma extrinsic pathway inhibitor activity. I. Standardization of assay and evaluation of physiologic variables
19. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
20. Molecular events that control the protein C anti-coagulant pathway
21. Thrombin regulation in mother and fetus during pregnancy
22. Thrombin receptor antagonists
23. Thrombin regulation by physiological inhibitors: The role of vitronectin
24. Association of thrombin-antithrombin III complex with vitronectin in serum
25. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum
26. Ternary vitronectin-thrombin-antithrombin III complexes in human plasma: Detection and mode of association
27. Progestin regulation of plasminogen activator inhibitor type-1 in primary cultures of endometrial stromal and decidual cells
28. Changes in plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia
29. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1)
30. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor
31. Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1
32. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin
33. Alteration of serpin specificity by a protein cofactor: Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties
34. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolytic resistance. Studies with thrombin generated in the Chandler loop
35. Thrombin regulation by physiological inhibitors: The role of vitronectin
36. The immunobiology and obstetrical consequences of antiphospholipid antibodies
37. Mutation in blood coagulation factor V associated with resistance to activated protein C
38. Association of idiopathic venous thrombembolism with single pointmutation at Arg 506 of factor V
39. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
40. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
41. World distribution of factor V Leiden
42. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
43. Resistance to activated protein C as a basis for venous thrombosis
44. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia
45. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
46. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestogen
47. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis
48. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis
49. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives
50. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy
51. Activated protein C resistance can be associated with recurrent fetal loss
52. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction
53. The factor V Leiden mutation may predispose women to severe preeclampsia
54. Factor V Leiden mutation: An unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis
55. Thromboembolism in pregnancy: An overview
56. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
57. Increased risk for venous thrombosis in carriers of the prothrombin G(A20210) gene variant
58. Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages
59. Plasminogen-activator inhibitor type-1 and coronary artery disease
60. Guidelines for the management of thrombophilia
61. Inherited hypercoagulable states
62. Antithrombin mutation database: 2nd (1997) update
63. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases
64. Prevalence of antithrombin deficiency in the health population
65. Absence of thrombosis in subjects with heterozygous protein C deficiency
66. Routine screening for coagulation inhibitors prior to prescribing the pill: Prevalence data from a large cohort of German pill starters
67. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect
68. Inherited protein S deficiency: Clinical manifestations and laboratory findings in 63 patients
69. Hereditary protein S deficiency: Clinical manifestations
70. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women
71. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management
72. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations
73. Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis
74. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies
75. Hyperhomo-cysteinemia: A risk factor in women with unexplained recurrent early pregnancy loss
76. Hyperhomo-cysteinemia as a risk factor for deep-vein thrombosis
77. High levels of coagulation factor XI as a risk factor for venous thrombosis
78. High plasma levels of factor VIII and the risk of recurrent thromboembolism
79. Risk factors for venous thrombotic disease
80. High levels of factor IX increase the risk of venous thrombosis
81. Heparin
82. Heparin: New concepts relevant to clinical use
83. Risks to the fetus of anticoagulant therapy during pregnancy
84. Heparin therapy during pregnancy. Risks to the fetus and mother
85. Low molecular weight heparin
86. Management of venous thromboembolism
87. Heparin osteoporosis
88. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
89. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
90. Low molecular weight heparins and their use in obstetrics and gynecology
91. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
92. Birth outcomes in pregnant women treated with low-molecular-weight heparin
93. Low-molecular-weight heparin for thrombophilia in pregnant women
94. Safety of low-molecular-weight heparin in pregnancy: A systematic review
95. Dalteparin: A low-molecular-weight heparin
96. Low molecular weight heparin, heparin, and warfarin